Boston Scientific, Inc. (BSX) has entered a definitive agreement to acquire Valencia Technologies Corporation, which develops the FDA-approved eCoin System, an implantable device for treating urge urinary incontinence (UUI). The acquisition is expected to be completed in the first half of 2026, pending customary closing conditions, although financial details have not been disclosed.
Approximately 30 million U.S. adults aged 40 and older experience significant symptoms of overactive bladder, affecting quality of life. In clinical trials, 68% of patients using the eCoin device achieved at least a 50% reduction in UUI episodes. This acquisition aims to enhance Boston Scientific’s Urology business by expanding its product offerings in minimally invasive bladder treatment options.
Currently, Boston Scientific boasts a market capitalization of $139.56 billion, with an anticipated 21.1% year-over-year improvement in EPS for 2025. Over the last three months, BSX shares have seen a decline of 4.2%, contrasting with a 6.8% fall in the industry.
